Global Antidiabetics Market is Anticipated to Reach USD 84.13 Billion by 2020: Market Research by Hexa Reports

Share this news:

Insulin was the most revenue generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of "antidiabetics market".

Global antidiabetics market is expected to reach USD 84.13 billion by 2020. Growing prevalence of diabetes is the primary driver of this market. Growth in prevalence of disease causing lifestyle disorders such as irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. Introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Long acting insulin was the leading product segment in 2013 and is expected to grow at the CAGR of over 15.0% during the forecast period. The introduction of advanced products, high prices associated with these products and the phasing out of human insulin are some key factors attributing for its large share.

Rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina and Onglyza on account of their once daily dosage regimens and safety profiles catalyzed the growth of this market.

Browse Related Category Market Reports @ http://www.hexareports.com/category/pharmaceutical-market

North America was the most matured antidiabetics market in 2013 accounting for over 43.0% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.

Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.

Some key market players of antidiabetics include Sanofi Aventis, Takeda Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals Inc., Merck & Co. Inc., Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics and Pfizer.

The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

Request a Sample Copy of the "Antidiabetics Market" Report @ http://www.hexareports.com/sample/42542

For the purpose of this study, Grand View Research has segmented the global antidiabetics market on the basis of product and region:

Global Insulin Product Outlook (Revenue, USD Million, 2012 - 2020)
Rapid acting
Long acting
Premixed
Premixed analog
Short acting
Intermediate acting

Global Antidiabetics Product Outlook (Revenue, USD Million, 2012 - 2020)
Alpha-glucosidase inhibitors
Biguanides
Sulphonylureas
GLP-1 agonist
Meglitinides
DPP-4 inhibitors
SGLT - 2
Thiazolodinediones

Antidiabetics Regional Outlook (Revenue, USD Million, 2012 - 2020)
North America
Europe
Asia Pacific
RoW

About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe.We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Info:
Name: Ryan Shaw
Email: Send Email
Organization: Hexa Reports
Address: Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States
Phone: 1-800-489-3075
Website: http://www.hexareports.com/report/antidiabetics-market-analysis-by-product-insulin-biguanides-thiazolodinediones-glp-agonists-sulphonylureas-dpp-4-inhibitors-sglt-2-alpha-glucosidase-inhibitors-meglitinides-and-segment-forecasts-to-2020/details

Release ID: 124949

SUBSCRIBE FOR MORE